https://triplehair.ca/triple-hair-expands-global-phase-iii-program-for-th07-with-launch-of-500-patient-trial-in-india/2026-08-11T09:37:29+01:00https://triplehair.ca/triple-hair-doses-first-patient-in-phase-iii-clinical-trial-in-canada-for-male-androgenic-alopecia/2026-08-11T09:34:17+01:00https://triplehair.ca/triple-hairs-feature-in-the-ny-post/2026-08-11T09:45:36+01:00https://triplehair.ca/triple-hair-group-signs-licensing-agreement-for-the-brazilian-market-with-ache/2026-08-11T10:41:32+01:00https://triplehair.ca/triple-hair-group-strengthens-leadership-team-with-appointment-of-paul-sowyrda-to-its-board-of-directors/2026-08-11T10:42:15+01:00https://triplehair.ca/th07-clinical-study-featured-in-peer-reviewed-scientific-journal/2026-08-11T10:42:45+01:00https://triplehair.ca/triple-hair-group-enters-into-licensing-agreement-with-akums-for-therapy-07-in-india/2026-08-11T10:30:59+01:00https://triplehair.ca/triple-hair-group-receives-ema-approval-to-start-phase-iii-clinical-trials-on-its-therapy-07-prescription-drug-in-europe/2026-08-11T10:37:10+01:00https://triplehair.ca/triple-hairs-feature-in-le-journal-de-montreal/2026-08-11T10:43:14+01:00https://triplehair.ca/triple-hair-group-closes-4-million-financing/2026-08-11T10:48:06+01:00